Carfilzomib
| 證據等級: L5 | 預測適應症: 5 個 |
目錄
Carfilzomib: From Multiple Myeloma to CMM7
One-Sentence Summary
Carfilzomib is a second-generation proteasome inhibitor; literature within this evidence pack identifies it as a frontline anti-myeloma agent, though no structured original-indication data was returned for this drug. The TxGNN model predicts it may be effective for CMM7 (familial cutaneous malignant melanoma type 7), but this is currently a pure model prediction with 0 clinical trials and 0 publications specifically supporting it. Given the complete absence of direct evidence, this candidate sits at evidence level L5 and the recommended decision is Hold.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Multiple Myeloma (inferred from literature context in this pack; not present in structured indication/license fields) |
| Predicted New Indication | CMM7 (familial cutaneous malignant melanoma type 7) |
| TxGNN Prediction Score | 99.37% |
| Evidence Level | L5 |
| Finland Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, no structured mechanism-of-action data is recorded for carfilzomib in this evidence pack (original_moa: [Data Gap]). However, contextual information elsewhere in the pack describes carfilzomib as a second-generation, irreversible proteasome inhibitor that blocks the chymotrypsin-like activity of the 26S proteasome, causing accumulation of misfolded proteins, NF-κB pathway dysregulation, and apoptosis — a mechanism established in the treatment of multiple myeloma.
For the CMM7 prediction specifically, the model's own rationale states there is no known direct mechanistic link between carfilzomib's proteasome-inhibition pathway and CMM7, a familial melanoma subtype most associated with germline POT1 and other telomere/DNA-repair gene variants. This prediction appears to be a broad extrapolation from the general "melanoma" disease category rather than a CMM7-specific signal.
Separately (not part of this specific candidate), this evidence pack does contain preclinical literature on carfilzomib in melanoma more generally — five papers, mostly cell-line and in-silico studies, showing pro-apoptotic effects in B16-F1 melanoma cells and molecular-docking activity against melanoma-relevant kinases. None of this literature addresses CMM7 or its POT1-driven biology, so it does not directly strengthen the present prediction, but it does indicate the broader "melanoma" category is not entirely mechanistically unexplored for this drug.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Finland Market Information
Carfilzomib is currently not marketed in Finland; no authorization records exist in the evidence pack.
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted therapy (proteasome inhibitor) |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Please refer to the package insert warnings and precautions |
| Handling Protection | Please refer to the package insert warnings and precautions |
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The CMM7 prediction is supported only by a TxGNN model score (L5, S0) with zero clinical trials and zero publications, and the mechanistic rationale itself confirms no known link between carfilzomib's proteasome-inhibition pathway and CMM7's POT1/telomere-driven biology. There is no evidence basis to advance this candidate at this time.
To proceed, the following is needed:
- TFDA/manufacturer package insert (warnings, contraindications) — currently a Blocking data gap (DG001)
- Formal, structured mechanism-of-action data from DrugBank or equivalent (DG002)
- Preclinical or mechanistic studies directly linking proteasome inhibition to POT1-mutant/CMM7 melanoma biology
- Any real-world or observational signal (even off-label) connecting carfilzomib to familial melanoma subtypes
- Finland market/regulatory pathway assessment, given the drug is not currently marketed there
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.